CN1163262C - Osteogenic growth peptide medicine composite and its preparation and application - Google Patents
Osteogenic growth peptide medicine composite and its preparation and application Download PDFInfo
- Publication number
- CN1163262C CN1163262C CNB991135962A CN99113596A CN1163262C CN 1163262 C CN1163262 C CN 1163262C CN B991135962 A CNB991135962 A CN B991135962A CN 99113596 A CN99113596 A CN 99113596A CN 1163262 C CN1163262 C CN 1163262C
- Authority
- CN
- China
- Prior art keywords
- ogp
- bone
- group
- peptide
- resin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Abstract
The present invention relates to a medicine composite containing osteogenic growth peptide (OGP). The OGP of the present invention is artificially synthesized and has the same structure as OGP structure naturally existing in blood serum. The medicine composite has the functions of promoting the proliferation of osteoblasts and fibroblasts, promoting the osteogenic effect of organisms, increasing the density of bone trabecula and preventing bone mass from losing. The medicine composite has wide application prospect in preventing and curing osteoporosis and curing fractures. The present invention also provides a preparation method.
Description
The invention belongs to biological preparation, be specifically related to a kind of pharmaceutical composition and preparation method and application that contains osteogenic growth peptide.
Osteogenic growth peptide (Osteogenic Growth Peptide) is a kind of 14-amino acid polypeptide that can promote the osteocyte growth of finding in the humans and animals body in recent years, behind body fracture or bone marrow injury, except the part at fracture or impaired bone marrow has the osteogenic response, also with osteogenic response [Bab I, et al. (1985) the Calcif Tissue Int.37:551-555 of whole body; Foldes J, et al. (1989) J Bone Miner Res.4:643-646]. show through deep experimentation, the myeloid tissue of healing can discharge several promotion osteogenic factors and enter blood circulation and cause the enhancing of whole body osteogenic response, confirm after deliberation and separate, purify, it is osteogenic growth peptide (Osteogenic Growth Peptide that a kind of factor is arranged, OGP) [Bab I, et al. (1988) Endocrinology 123:345-352; Bab I, et al. (1992) EMBO J 11:1867-1873].Studies show that further the aminoacid sequence of OGP is ALKRQRGTLYGFGG, this sequence is on all four the mice and the mankind, and its action characteristic is also identical.
Relevant experiment in vitro studies show that, the OGP of synthetic (consistent with naturally occurring OGP structure in the serum) acts on ROS, MC3T3, E1 and the NH3T3 fibroblast of osteoblast system, has the effect that promotes that osteoblast and fibroblast proliferation, alkaline phosphatase activities increase.Find also that in addition its effect transfers inhibition on the contrary to, that is to say that the effect of OGP manifests two-way performance after OGP concentration surpasses a certain critical point in the serum.
About experiment report and our preliminary experiment in the body studies show that the OGP of synthetic injects in the rat body can promote osteoblastic proliferation, promotes the body ossification, improves bone trabecula density.
The purpose of this invention is to provide the OGP polypeptide with following general structure or the pharmaceutical composition of its pharmaceutically acceptable salt:
R
1-Ala-Leu-Lys-Arg-Glu-Arg-Gly-Thr-Leu-Tyr-Gly-Phe-Gly-Gly-R
2
R wherein
1Representative is selected from CH
3COO-or NH
2-end; R
2Representative-NH
2Or-the OH end.
Wherein said pharmaceutical composition is formed as active ingredient and pharmaceutical carrier with the OGP polypeptide, and can to contain OGP be 0.01～99.99% to be that 99.99%～0.01% arbitrary proportion is made into 100% composition with containing medicinal carrier.
Can use conventional chemistry of peptides synthetic technology, with main component OGP in the pharmaceutical composition of solid phase method or the synthetic OGP of the present invention of liquid phase process, but better be to use solid phase synthesis process (for example referring to Birr, C., Aspect of the Merrifield Peptide Synthesis, Springer-Verlag, Heidelberg, 1978; Stewart et al., Solid Phase PeptideSynthesis, 2nd.ed., Pierce Chem.Co., Rockford, IL, 1984; Barany, G.and Merrifield R.B.in The Peptides, Vol.2; Gross, E.﹠amp; Meienhoffer J., eds., Academic Press, New York, pp3-284,1979).Also can recombinant DNA technology make.
Another object of the present invention has provided the preparation method of above-mentioned osteogenic growth peptide (OGP polypeptide); this method utilizes suitable activator and condensing agent to be connected on the solid phase carrier through the peptide chain C-terminal amino acid residue of due care radical protection according to that designed and given aminoacid sequence.Wherein said solid phase carrier is polystyrene, polyacrylamide resin, Kiseseguhr polyamide, the glass fibre in control aperture or the polystyrene support of globule, cellulose, polypropylene screen and acrylic acid bag quilt of divinylbenzene crosslink.Preferred solid phase carrier comprise divinylbenzene crosslink acrylic resin, chloromethyl resin, hydroxymethyl resin, para-position acetonyl resin .alpha.-aminodiphenylmethane. (BHA) resin, 4-methyldiphenyl methylamine (MBHA) resin, 4-(2 ',-4 '-the Dimethoxyphenyl aminomethyl)-phenoxymethyl resin, 2,4-dimethoxy benzene mexan resin and (2,4-Dimethoxyphenyl-Fmoc-aminomethyl)-phenoxy group acetylaminohydroxyphenylarsonic acid norleucyl--mbha resin (being Rink Amide mbha resin).
The blocking group of preferred a-amino acid is 9-fluorenes methoxy carbonyl acyl group (Fmoc) blocking group.
When using the Fmoc system to carry out solid phase synthesis, can select following protected amino acid residue: Fmoc-Leu for use, Fmoc-Thr (But), Fmoc-Gly, Fmoc-Lys (Boc), Fmoc-Gln, Fmoc-Tyr (But) and Fmoc-Arg (PMC).When using the Boc system to carry out solid phase synthesis, can select following protected amino acid residue: Boc-Lys (ClZ) for use, Boc-Thr (Bzl), B0c-Leu, Boc-Gly, Boc-Arg (Tos), Boc-Gln, Boc-Tyr (Brz).
Can use known various coupling agents and each amino acid residue of coupling method coupling in the synthetic field of chemistry of peptides, for example can use DIC (DIC), dicyclohexylcarbodiimide (DCC) to carry out direct coupling, or pass through for example pentafluorophenyl esters of active ester, or use Fmoc-aminoacid-carboxylic acid anhydrides.Can use hydroxyl benzotriazole (HOBt) or 7-azepine hydroxy benzenes a pair of horses going side by side triazole (HOAt) or with 2-(1H-benzene parallel triazol-1-yl), 1,1,3,3-four urea hexafluorophosphoric acid ester (HBTU) activated amino acids.
Method or synthesizer are finished the synthetic of above-mentioned human calcitonin analogue polypeptide by hand, but for simplicity, preferably use the polypeptide automatic synthesizer that is commercially available, for example ABI 430A type or the ABI 431A type peptide of producing by Applied Biosystems company.In the Fmoc synthesis system, at first C is held first aminoacid (C holds Fmoc-Pro) to be contained in the reactor of hydroxy-containing resin, extend to the N end one by one by the C end according to given aminoacid sequence.Wherein protect various amino acid whose alpha-amidos with Fmoc.Each amino acid whose Side chain protective group is respectively: Thr protects with the tert-butyl group (But); Arg protects with Mtr; Lys protects with Boc; Tyr protects with But.Use HOBT and DCC to activate each amino acid whose carboxylic end, and finish the condensation between amino acid molecular.
After synthetic the finishing, synthetic OGP peptide is cut down and removes each protecting group from resin with the trifluoroacetic acid aqueous solution that contains or do not contain Reducing agent (as mercaptoethanol).Available Filtration or the separation of ether sedimentation method obtain thick peptide.After the solution lyophilizing with products therefrom, with gel filtration or the required peptide of reverse phase HPLC method purification.
In the solid phase synthesis of Boc protection system, be typically and use the PAM resin.Different is to protect each seed amino acid alpha-amido with Boc.The amino acid side chain blocking group is respectively: Lys protects epsilon-amino with oxygen benzyloxy carbonyl (CL-Z); Arg uses benzyl (Bzl) to protect pendant hydroxyl group with tosyl (Tos) protection, Thr; Tyr protects with BrZ.In going protection, neutralization, link coupled circulation, remove blocking group (Boc) and use diisopropylethylamine (DIEA)/dichloromethane neutralization with TFA/ dichloromethane (DCM).After the peptide chain condensation is finished,, handled 1-2 hour down, peptide chain is downcut from resin, remove all blocking groups simultaneously at 0 ℃ with the fluohydric acid gas (HF) that contains paracresol (5-10%).With 10%-50% acetic acid (containing a small amount of mercaptoethanol) extracting peptide, and carry out the oxidation of polypeptide.Further use molecular sieve Sephadex G10 or Tsk-40f separation and purification after the lyophilizing, and then through high pressure liquid chromatography C
8Column purification obtains the pure OGP polypeptide of HPLC.
Available known method will be made its pharmaceutically acceptable salt as stated above or with the OGP peptide that recombinant DNA technology makes, particularly base addition salts.For example, can with these peptides of suitable alkali treatment, make the base addition salts of acidic amino acid by method well known to those skilled in the art.
Can OGP of the present invention be made the suitable pharmaceutical composition of specific administration mode clinically by the known conventional method of pharmaceutical field.For example can in calcitonin-like of the present invention, add appropriate carriers or diluent, as water, normal saline, etc. ooze glucose solution can be to make through solution, injection, Emulsion, nasal drop, the eye drop of administration beyond the gastrointestinal tract.Also can add excipient or carriers such as starch, lactose, Pulvis Talci, sucrose, glucose or glycerol, liquid paraffin, liposome or gelatin, OGP of the present invention is made can be through suppository, tablet, powder, granule, capsule or the liposome agent of gastrointestinal tract administration.In these preparations except that containing active component and appropriate carriers or excipient, also can add some other auxiliary element, for example one or more diluent, filler, emulsifying agent, antiseptic, surfactant, absorption enhancer, buffer agent, flavouring agent and coloring agent as required.
A further object of the present invention provides aforementioned pharmaceutical compositions tool in people and mammalian body and improves osteoblast, and fibroblastic activity increases the bone amount, prevents bone loss.And be used for control and treatment osteoporosis in preparation, and promote the fractured bones healing, shorten the application in the medicine of healing time and traumatic wounds healing.
The interior experimental result of the body that we utilize the osteoporosis rat model to be done shows, with generally use clinically at present and have a stronger high bone mass of carrying, the salmon calcitonin see calcimar that prevents bone loss is compared, OGP pharmaceutical composition of the present invention has the osteoblast of raising and fibroblastic activity, promote the bone amount to increase simultaneously, prevent bone loss.Compare, salmon calcitonin see calcimar mainly is to reach by the activity that suppresses osteoclast to carry high bone mass, and OGP pharmaceutical composition of the present invention mainly promotes osteoblastic activity, carries high bone mass by the increase of skeletonization, have the high bone mass of carrying peak value, slow down advantages such as bone loss time.Can be used for prevention and treatment union of fracture and osteoporosis, promote the effects such as healing of fracture back knitting and traumatic wounds.In addition, the main component of performance drug action has and naturally occurring people OGP identical in structure structure in the pharmaceutical composition of OGP of the present invention, thereby has significantly avoided the immunogenicity that may cause behind the life-time service.
As previously mentioned, the pharmaceutical composition of OGP of the present invention has significant raising osteoblast and fibroblastic activity, promotes the bone amount to increase simultaneously, prevents the bone loss effect.Be better than the present salmon calcitonin see calcimar that generally uses clinically.Salmon calcitonin see calcimar relatively, it mainly is to suppress the activity of osteoclast and reach and carry high bone mass, and OGP drug regimen of the present invention mainly promotes osteoblastic activity, carries high bone mass by the increase of skeletonization.Have the high bone mass of carrying peak value, slow down the advantage of bone loss time.
Osteogenic growth peptide promotes the research of bone amount in the osteoporosis animal model
The research that this laboratory observation osteogenic growth peptide (OGP) increases the bone amount is for the treatment osteoporosis finds safe and effective medicine.
With 50 SD rats, Mus 12 weeks of age, weight average 240 grams, the low calcium feedstuff of warp (Ca:0.1%, P:0.6%), raising became osteoporosis model in 6 months, was divided into 5 groups then at random, and 10 every group, (Ca:1.1% P:1.1%), feeds to change normal diet into.Grouping experiment is as follows: A organizes (low dosage OGP) 0.2ug/0.5ml; B organizes (high dose OGP) 2ug/0.5ml; C organizes (salmon calcitonin see calcimar) 0.1ug/0.5ml; D group (normal saline) 0.5ml contrast, injection, totally 12 weeks next day that napex being subcutaneous respectively.Carry out following detection then.
1) bone densitometry: only randomly draw 6-7 for every group, totally 33, the pentobarbital sodium with 0.25% (50mg/kg body weight) carries out intraperitoneal anesthesia, measures the bone density (BMD) of lumbar vertebra 3 levels, right side neck of femur and tibia upper end respectively.
2) heart blood sampling 5ml carries out the mensuration of serum alkaline phosphatase (AKP) and Bone Gla protein (BGP) respectively.
3) osseous tissue morphology metering: rat was put to death preceding 14 days, and every day is with 0.25% quadracycline (35ml/kg) intraperitoneal injection 2 days, again in putting to death preceding 4 days, with same dosage injection 2 days.After the excessive pentobarbital sodium intraperitoneal anesthesia, intercepting waist 3 vertebral bodys are removed soft tissue, acetone fixed, and pure rising gradient dehydration is carried out cone and is lost the discontinuous undecalcified section of shape face after the methyl methacrylate embedding, and thickness is two kinds of 12 μ and 5 μ.12 μ section is observed usefulness for fluorescent staining not, and 5 μ cut into slices and use 1% Toluidine blue staining.Section is observed with Olympus Vanox-1 microscope.The structure measurement parameter is analyzed with automatic graphics software Mias-300: 1. TBV (%) is a Trabecula Bone Volume in the certain limit section; 2. bone trabecula mean breadth, MTT (μ m); 3. cortical bone average thickness, MTC (μ m).
4) scanning electron microscopic observation: get waist 3 cones, remove soft tissue, with its cross-section cutting, normal saline flushing is clean, earlier with 2.5% glutaraldehyde and 1% osmic acid double fixed, and serial dehydration of alcohol, n-Amyl acetate displacement, CO
2Critical point drying (HCP-2 type), ion sputtering instrument (IB-3 type) metal spraying is used the S-520 of Hitachi scanning electron microscopic observation then.
5) transmission electron microscope observing: with right lateral thigh bone along frontal plane to cuing open, fix 2 hours with 2.5% glutaraldehyde, the dehydration of gradient ethanol, acetone, epoxy resin embedding, the section of LKB-1 type ultramicrotome, JEM-1200EX transmission electron microscope observing.
6) statistical procedures: total data is all carried out variance analysis and t check.
It is as described below that each detects index:
1, the 12nd when week SD rat body weight measurement result:
Table 1 is respectively organized measured body weight result (g)
Group A B C D
Other n=10 n=10 n=10 n=10
Meansigma methods 446.5 ± 21.8 445.5 ± 21.2 447.0 ± 24.4 449.0 ± 26.4
As can be seen from Table 1, each group of A, B, C and D is more or less the same, through the t check, and P＞0.05, zero difference on the statistics is respectively organized rat body weight and is not had significant change after the illustrative experiment medication.
2, bone density measurement result:
Femur, tibia, lumbar vertebra BMD value of each group of table 2 (X ± SD, g/cm)
Group femur and tibia pelvic bone
A(n＝7) 0.2548±0.0177 0.2623±0.0234 0.2434±0.0270
B(n＝7) 0.2742±0.0264 0.2649±0.0258 0.2816±0.0667
C(n＝6) 0.2635±0.0517 0.2997±0.0416 0.2675±0.0320
D(n＝6) 0.1741±00.0241 0.1686±0.0177 0.1880±00093
As can be seen from Table 2, femur, tibia, the lumbar vertebra BMD value of D group is starkly lower than A, B, each group of C, through the t check, and P＜0.01, there were significant differences on the statistics.And between each group of A, B, C, through the t check, zero difference on P＞0.05 statistics.The matched group sclerotin is obviously loose after the illustrative experiment medication, and treatment group bone density rises, and the prompting treatment effectively.
3, serum alkaline phosphatase (AKP) and Bone Gla protein (BGP) measurement result:
The table 3-1 respectively organize serum alkaline phosphatase (AKP) measurement result (X ± SD, U/L)
Group A B C D
Other n=10 n=10 n=10 n=10
Meansigma methods 169.7 ± 16.4 165.8 ± 11.7 100.8 ± 9.3 83.4 ± 9.5
From 3-1 as can be seen, A, B organize apparently higher than D for two groups, and there is highly significant difference P＜0.001 on the statistics.A, B also are higher than the C group for two groups simultaneously, and there is significant difference P＜0.01.And between C group and the E group, P＞0.05, zero difference.It is more effective than salmon calcitonin see calcimar on the content that improves the AKP enzyme to be illustrated as bone peptide, and salmon calcitonin see calcimar is little to facilitation on the raising AKP enzyme content.
The table 3-2 respectively organize serum osteocalcin (BGP) measurement result (X ± SD, ng/ml)
Group A B C D
Other n=10 n=10 n=10 n=10
Meansigma methods 2.17 ± 0.20 2.02 ± 0.19 1.43.8 ± 0.15 1.21 ± 0.09
Show 3-2 as can be seen, between two groups of A, B and the D group, P＜0.05, difference on the statistics.And C group and D group, P＞0.05, zero difference.Be illustrated as bone peptide and can improve Bone Gla protein (BGP) content, and the salmon calcitonin see calcimar effect is little.
4, osseous tissue norphometry result:
Table 4 respectively organize lumbar vertebra tissue morphology metering result (X ± S, n=4)
Group TBV MTT MTC
A 37.16±2.56 152.35±8.49 250.93±20.81
B 38.35±2.95 145.10±10.05 249.66±20.72
C 37.62±2.89 147.83±10.60 248.57±21.14
D 15.08±1.38 64.66±4.93 238.69±14.37
As can be seen from Table 4, between A, B, each group of C and the D group, there is highly significant difference P＜0.001.And between each group of A, B, C, P＞0.05, zero difference.Illustrate that the treatment group carrying high bone mass, prevent that the aspect is better than matched group on the bone loss.
5, scanning electron microscopic observation result: normal saline matched group bone trabecula has destruction, absorption, shows as bone trabecula and attenuates, comes to a point, ruptures, and the space between bone trabecula increases, and bone trabecula is indicated existing bone resorption (Fig. 1) under the high power lens.The OGP treatment organizes that then bone trabecula is thick, complete, seriality good (Fig. 2).
6, transmission electron microscope observing result: normal saline matched group osteocyte many places are in the regression phase, the karyon pyknosis, and nuclear/slurry ratio is big, more cavity occurs, and kytoplasm reduces, and lacuna gap floccule increases, and the lacuna wall has the osmium of having a liking for flaggy (Fig. 3).And OGP treatment group osteocyte many places are in becoming bone photo, and kytoplasm is abundant, and nuclear/slurry ratio is little, lacuna gap little (Fig. 4).
7, observation by light microscope result: the light microscopic performance of normal saline matched group bone trabecula undecalcified section, bone trabecula attenuates (Fig. 5), and the light microscopic performance of OGP treatment group bone trabecula undecalcified section, bone trabecula is thick, seriality complete (Fig. 6).Normal saline matched group undecalcified section, fluorescent labeling is less, dark (Fig. 7), and the section of OGP treatment group undecalcified, fluorescent labeling more, brighter (Fig. 8).
The OGP of synthetic has the osteoblast of promotion and fibroblast proliferation, improve the activity of osteoblast AKP, increase whole body bone formation and bone trabecular volume, prevent bone loss, also can induce the new bone in the osteoporosis treatment to gather, improve the biomechanics characteristic of bone.Promote the healing of the injured back of body wound, promote the bone marrow healing of damaged, for osteoporosis and fractures provide a new approach.
Fig. 1 normal saline matched group bone trabecula attenuates, the gap increase (SEM, X100)
Fig. 2 OGP treatment group bone trabecula is thick, the gap is little, seriality complete (SEM, X100)
Fig. 3 matched group osteocyte is that regression phase, karyopycnosis, endochylema are few, lacuna enlarge (TEM, X6000)
Fig. 4 OGP treatment group osteocyte is into bone photo, more Cytoplasm and organelle are arranged, lacuna narrow and small (TEM, X6000)
The light microscopic performance of Fig. 5 matched group bone trabecula undecalcified section, bone trabecula attenuates, and (toluidine blue dyes, X100)
The light microscopic performance of Fig. 6 OGP treatment group bone trabecula undecalcified section, bone trabecula is thick, and seriality is complete, and (toluidine blue dyes, X100)
Fig. 7 matched group undecalcified section, fluorescent labeling less, dark (fluorescence microscope, X100)
Fig. 8 OGP treatment group undecalcified section, fluorescent labeling more, brighter (fluorescence microscope, X100)
The consumption of pharmaceutical composition of the present invention will depend on the many factors such as the character of disease to be treated and the order of severity, patient's body weight, general health situation, method of administration. In general, about 0.5 to 5 microgram of consumption per kilogram of body weight every day of pharmaceutical composition of the present invention, preferably 1-2 microgram/per kilogram of body weight.
Can use pharmaceutical composition of the present invention by various conventional methods of administration, such as can be in intestines and stomach, in subcutaneous, the intracutaneous, nose, in the intravenous, muscle, in the rectum, the administration such as intraocular, but wherein preferred method of administration is intramuscular injection, hypodermic injection, nose spraying or oral administration.
Embodiment 1:
(1) with synthetic array structure (1) the OGP peptide down of Boc system:
NH
2-Ala-Leu-Lys-Arg-Glu-Arg-Gly-Thr-Leu-Try-Gly-Phe-Gly-Gly-OH(1)
(1g 0.5mmol) is loaded in the ABI 430 automatic Peptide synthesizer reactors, and step shown in the according to the form below is held each protected aminoacid of condensation by the C end to N with initial PAM resin.After each step, reaction was finished, remove each reagent from resin through positive pressure of nitrogen effect filtration.Wherein C holds in the condensation reaction according to the form below of first protected aminoacid Boc-Gly and resin the 5th～14 step to carry out, and all the other amino acid whose condensations are all undertaken by the 1st～14 step.
| Step | Reagent | Reagent dosage (ml) | Number of repetition | Incorporation time (branch) |
| 1 | DCM | 30 | 3 | 2 |
| 2 | TFA/DCM | 30 | 1 | |
| 3 | TFA/DCM | 30 | 15 | |
| 4 | DCM | 30 | 3 | 2 |
| 5 | DIEA/DMF | 30 | 1 | |
| 6 | DIEA/DMF | 30 | 10 | |
| 7 | DMF | 30 | 3 | 2 |
| 8 | DCM | 30 | 3 | 2 |
| 9 | Boc-aminoacid, 2mmol HOBT/DCC is dissolved in DMF | 20 | 120 | |
| 10 | DCM | 30 | 3 | 2 |
| 11 | DMF | 30 | 3 | 2 |
| 12 | DCM | 30 | 3 | 2 |
| 13 | Boc-aminoacid, 1mmol HOBT/DCC is dissolved in DMF | 20 | 120 | |
| 14 | Repeat 10～12 steps | |||
| 15 | Repeated for 1～14 step and carry out the extension that the C terminal amino acid is held to N one by one |
Each amino acid condensation reaction was on average carried out 2 hours.Whenever measure free amine group to determine condensation whether fully [Kaiser E T, et al.Anal.Biochem.34:595-598,1969] with ninhydrin method before entering next amino acid condensation circulation.After the N end extends peptide chain, obtain purpose peptide chain resin by above-mentioned reactions steps one by one by the C terminal amino acid, carry out vacuum drying after resin is shifted out from reactor.
(2) fluohydric acid gas of peptide chain resin (HF) cleavage reaction
Exsiccant peptide chain resin (1g) and paracresol (ml) are placed reactor.In the cooling of the external dry ice of container/ethanol cryostat, and collect about 20ml liquid state HF, then stirring reaction 1 hour under ice bath.After reaction is finished, remove ice bath, HF is removed in evaporation under vacuum.In reactor, add anhydrous ethyl acetate with resin give a baby a bath on the third day after its birth time (each 30ml), elimination reagent then.With the thick peptide of 50% acetic acid extracting 2 times (each 5ml).Merge gained filtrate, with carrying out lyophilization after the dilution of 100ml deionized water to remove solvent.
(3) purification of the thick peptide of OGP
Take by weighing above-mentioned crude product 50mg, be dissolved in the 1ml 1N acetic acid, gained solution is crossed Sephadex G10 post, and (2.0 * 25cm), 1N acetic acid eluting is with desalination.Carry out lyophilization after collecting full row peak, get desalination crude product 37mg.Further with gained desalination product high pressure liquid on the contrary to chromatographic column Beckman Octyl C18,10mm * 25cm.Collect main peak, merge final vacuum and remove acetonitrile, and lyophilization.Sample purity behind the purification reaches more than 95%, and amino acid composition analysis and mass spectrometry results all meet theoretical value.
Embodiment 2:(1) with the synthetic OGP peptide of Fmoc system:
(1g 0.45mmol) is loaded in the 30ml bottle, and handles 30 minutes with DCM with initial Rink Amide hydroxy resin.Step shown in the according to the form below is held each protected aminoacid of condensation one by one by the C end to N.After per step, reaction was finished, filter each reagent of removal through suction function, and make it to separate with peptide resin.Wherein C holds in the condensation reaction according to the form below of first protected aminoacid Fmoc-Gly and resin step 1～15 to carry out, and all the other amino acid whose condensations are all undertaken by 1～15.
| Step | Reagent | Reagent dosage (ml) | Number of repetition | Incorporation time (branch) |
| 1 | DMF | 20 | 3 | 2 |
| 2 | Hexahydropyridine/DCM | 20 | 5 | |
| 3 | Hexahydropyridine/DCM | 20 | 15 | |
| 4 | DCM | 20 | 3 | 2 |
| 5 | DMF | 20 | 2 | |
| 6 | Dioxane/H 2O | 20 | 2 | |
| 7 | DMF | 20 | 3 | 2 |
| 8 | DCM | 20 | 3 | 2 |
| 9 | Fmoc-AA, 1.5mmol HOBT/DCC is dissolved in DMF | 15 | 120 | |
| 10 | DCM | 20 | 3 | 2 |
| 11 | Ethanol | 20 | 3 | 2 |
| 12 | DMF | 20 | 3 | 2 |
| 13 | DCM | 20 | 3 | 2 |
| 14 | Fmoc-AA, 0.5mmol HOBT/DCC is dissolved in DMF | 15 | 120 | |
| 15 | Repeat 10～13 steps | |||
| 16 | Repeat 1～15 and finish the extension that the C terminal amino acid is held to N one by one |
Each amino acid condensation reaction was on average carried out 2 hours.Whether whenever enter next amino acid condensation circulation preceding complete to determine condensation with ninhydrin method mensuration free amine group.After the N end extends peptide chain, obtain purpose peptide chain resin by above-mentioned reactions steps one by one by the C terminal amino acid, carry out vacuum drying after resin is shifted out from reactor.
(2) the TFA cleavage reaction of peptide chain resin
With exsiccant peptide chain resin (0.5g) with m-cresol (0.5ml) places reactor and ice bath pre-cooling 30 minutes.Add 0.5ml water, 9mlTFA stirring reaction 1 hour under condition of ice bath.The elimination reactant liquor, it is inferior by a small amount of TFA remaining resin to be given a baby a bath on the third day after its birth, and reuse DCM gives a baby a bath on the third day after its birth inferior, then merging filtrate.DCM and TFA are removed in the vacuum suction evaporation.Treat that liquid drains into when thick substantially, add the ethyl acetate of pre-cooling, separate out gradually after the jolting rapidly thick peptide of solid form and centrifugation it.
(3) purification process is with (3) method among the above-mentioned embodiment 1.
Every ampere of bottled OGP 100 μ g (HPLC identifies that purity reaches more than 98%)
20% mannitol 1ml
6% low molecular dextran 9mg low molecular dextran specification: molecular weight 10,000～20,000 meets the injection quality standard is dissolved in the 0.5ml ultra-pure water, and getting dried frozen aquatic products injection thinned water through lyophilization is normal saline, the each 1ml of consumption.
Claims (4)
1. the purposes of an osteogenic growth peptide is characterized in that, is used to prepare the medicine that improves BGP content.
2. purposes as claimed in claim 1 is characterized in that, described medicine contains the osteogenic growth peptide of 0.01-99.99% and the pharmaceutical carrier of 99.99-0.01%, by weight.
3. purposes as claimed in claim 1 is characterized in that, described medicine also is used to improve bone density simultaneously.
4. purposes as claimed in claim 1 is characterized in that, the amount of application of described medicine is the 0.2ug/240g body weight.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB991135962A CN1163262C (en) | 1999-04-01 | 1999-04-01 | Osteogenic growth peptide medicine composite and its preparation and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB991135962A CN1163262C (en) | 1999-04-01 | 1999-04-01 | Osteogenic growth peptide medicine composite and its preparation and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1269242A CN1269242A (en) | 2000-10-11 |
| CN1163262C true CN1163262C (en) | 2004-08-25 |
Family
ID=5276770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB991135962A Expired - Fee Related CN1163262C (en) | 1999-04-01 | 1999-04-01 | Osteogenic growth peptide medicine composite and its preparation and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1163262C (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EE200400062A (en) * | 2001-07-29 | 2004-06-15 | Yissum Research Development Company Of The Hebrewuniversity Of Jerusalem | Osteogenic growth oligopeptides as hematopoietic stimulators |
| BRPI0807506B1 (en) * | 2007-02-09 | 2022-02-15 | Acceleron Pharma, Inc | USE OF AN ACTRIIA-FC FUSION PROTEIN FOR THE MANUFACTURE OF A DRUG TO TREAT OR PREVENT MULTIPLE MYELOMA |
| CN102178655B (en) * | 2011-04-29 | 2012-08-15 | 济南环肽医药科技有限公司 | Preparation method of osteocalcin (OC) freeze-dried powder preparation for injection |
| CN103665109B (en) * | 2013-11-15 | 2016-01-20 | 陕西东大生化科技有限责任公司 | The synthetic method of C-terminal pentapeptide of osteogenic growth peptide |
| CN107213523B (en) * | 2017-06-13 | 2020-06-05 | 苏州大学附属第一医院 | Preparation method of co-crosslinked double-network hydrogel scaffold for promoting osteogenesis |
| WO2021042732A1 (en) * | 2019-09-06 | 2021-03-11 | 陕西慧康生物科技有限责任公司 | Osteogenic growth peptide carbon-terminal pentapeptide derivative, preparation method therefor, and use thereof |
-
1999
- 1999-04-01 CN CNB991135962A patent/CN1163262C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1269242A (en) | 2000-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100350971C (en) | Stimulation of bone growth with thrombin peptide derivatives | |
| CN1199340A (en) | Analogs of parathyroid hormone | |
| WO2021068550A1 (en) | Active polypeptide compound | |
| EP2794647B1 (en) | Novel gh-rh analogs with potent agonistic effects | |
| CN1163262C (en) | Osteogenic growth peptide medicine composite and its preparation and application | |
| BG65137B1 (en) | Antagonist analogs of gh-rh inhibiting igf-i and -ii | |
| AU578902B2 (en) | Insuliin-potentiating peptides from human growth hormome | |
| JP2715472B2 (en) | Cyclic peptide | |
| CN1105726C (en) | Human calcitonin analogue | |
| CN1219548C (en) | Join of C peptide and insulin for treating diabetes complication and C peptide-specific antibody | |
| CN1271365A (en) | Compounds with anti-KS and anti-HIV activity | |
| US9464128B2 (en) | Site-specific pegylated linear salmon calcitonin analogues | |
| CN1136229C (en) | Action of proinsulin associated peptide on dopamine transporter and its application in treating correlative diseases | |
| CN1785424A (en) | Bone growth penta peptide medicinal composition ant its preparation method | |
| CN1683408A (en) | Glucagon-like peptide analog, its composition and its using method | |
| CN1746185A (en) | Analog of Exendin 4 | |
| CN1240436C (en) | Synergistic action of ossification growth peptide and granule cell colony stimulating factor in hematopoiesis | |
| CN1634980A (en) | Analogues of orphanin FQ | |
| CN1421456A (en) | Human apolipoprotein polypeptide and its use in resisting vascular proliferation diseases | |
| CN1138864A (en) | New compsn. of glycoprotein isoforms having follicle stimulating | |
| CN1916025A (en) | Analogs of parathyroid hormone |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: SHANGHAI INST. OF BIOCHEMISTRY, CHINESE ACADEMY OF SCIENCES Effective date: 20031015 Owner name: SHANGHAI YIZHONG BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: ZHONGSHAN AFFILIATED HOSPITAL OF SHANGHAI MEDICAL UNIVERSITY |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20031015 Address after: 200203, room 288, 101 Li Shizhen Road, Zhangjiang hi tech park, Shanghai, Pudong New Area Applicant after: Shanghai Yizhong Biotechnology Co. Ltd. Address before: 200032 No. 136, Shanghai Medical College Road Applicant before: Zhongshan Hospital Attached to Shanghai Medical Univ. Co-applicant before: Shanghai Research Institute of Biochemistry Chinese Academy of Sciences |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20040825 Termination date: 20110401 |